**Table 2.13. Case–control studies of HPV and vaginal cancer**

| Reference, study location | Sites included | No. of cases | No. of controls | Method of detection | HPV prevalence (%) | | Odds ratio (95% CI) | Comments |
|---|---|---|---|---|---|---|---|---|
| | | | | | Cases | Controls | | |
| Carter *et al.* (2001), USA | Sera | 35 | 1804 | Seropositivity to HPV16 and HPV18 capsid proteins by ELISA (L1) | N=15/35 (42.9%) HPV16 L1 Ab | N=264/1804 (14.6%) HPV16 L1 Ab | 4.8 (2.4–9.5) | Sera |
| | | | | | N=4/8 (50%) HPV16 L1 Ab + HPV16 DNA | N=264/1804 (14.6%) HPV16 L1 Ab + HPV16 DNA | 6.3 (1.6–25.6) | |
| | | | | | N=8/35 (22.9%) HPV18 L1 Ab | N=258/1802 (14.3%) HPV18 L1 Ab | 1.8 (0.8–4.0) | |
| | | | | | N=1/2 (50%) HPV18 L1 Ab + HPV18 DNA | N=258/1802 (14.3%) HPV18 L1 Ab + HPV18 DNA | – | |
| Daling *et al.* (2002), USA | Sera from patients with no history of vaginal cancer | 37 | 2041 | Seropositivity to HPV16 and HPV18 capsid proteins by ELISA (L1) | N=15/35 (42.9%) HPV16 L1 Ab | N=263/1800 (14.6%) HPV16 L1 Ab | 4.3 (2.1–8.7) | Sera |
| | | | | | N=6/14 (42.9%) HPV16 L1 Ab + HPV16 DNA | N=263/1800 (14.6%) HPV16 L1 Ab + HPV16 DNA | 4.4 (1.5–13.0) | |
| | | | | | N=8/35 (22.9) HPV18 L1 Ab | N=257/1798 (14.3%) HPV18 L1 Ab | 1.6 (0.7–3.6) | |
| Madsen *et al.* (2008), Denmark | Controls were Corpus Uterine Cancer samples | 27 | 17 | GP5+/6+ PCR-EIA assay and type-specific for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 & 68 and other 23 low risk HPV. | N=24 (89%) | N=0 (0%) | – | Formalin-fixed paraffin-embedded tissue samples. [Controls are unlikely to harbour hPV]. |

DRAFT